

Special Issue

Perinatal-Related Pathology

Message from the Guest Editors

An increasing amount of data indicate that the majority of cases of the so-called great obstetrics syndrome are caused by dysfunction of the placenta, which is caused by its impaired development or too-early functional impairment. Pregnant women with clinical symptoms of placental insufficiency are still doomed to iatrogenic premature termination of pregnancy, and the severity of the pathology is correlated with perinatal outcomes. Therefore, it is worth looking for genetic, biochemical, and biophysical methods that can be used to monitor the course of the disease. A relationship is sought between the type of bacteria inhabiting the gastrointestinal tract of women and the occurrence of obesity, gestational diabetes, or premature birth, as well as hypoxia and intrauterine infection. Other metabolomes, such as maternal and newborn urine, amniotic fluid, human breast milk, and meconium of the newborn, are also tested. In research on the microbiome in the newborn, the relationship with civilization diseases, infections, and eating disorders is sought. Is it possible to get closer to personalized medicine by using metabolomics?

Guest Editors

Prof. Dr. Agnieszka Kordek

Department of Neonatology, Medical University in Szczecin, Poland, Poland

Dr. Andrzej Torbé

Department of Obstetrics and Gynecology, Pomeranian Medical University, Szczecin, Poland

Deadline for manuscript submissions

closed (31 December 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/113321

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).